REVIEW   Free access

Minerva Urologica e Nefrologica 2018 April;70(2):144-51

DOI: 10.23736/S0393-2249.17.03066-1

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Hormonal treatment and quality of life of prostate cancer patients: new evidence

Marcello TUCCI ¹ ✉, Gianmarco LEONE ¹, Consuelo BUTTIGLIERO ¹, Clizia ZICHI ¹, Rosario F. DI STEFANO ¹, Daniele PIGNATARO ¹, Francesca VIGNANI ², Giorgio V. SCAGLIOTTI ¹, Massimo DI MAIO ²

¹ Division of Medical Oncology, San Luigi Gonzaga Hospital, Department of Oncology, University of Turin, Orbassano, Turin, Italy; ² Division of Medical Oncology, Ordine Mauriziano Hospital, Department of Oncology, University of Turin, Turin, Italy

Androgen deprivation therapy (ADT) is the mainstay of treatment of patients with relapsed or metastatic hormone-sensitive prostatic carcinoma. The dramatic reduction of serum testosterone levels induced by ADT produces multiple side effects as vasomotor flushing, sexual dysfunction, fatigue, impairment of cognitive function, reduced quality of sleep, gynecomastia and anemia, that are able to decrease health-related quality of life (QoL). In addition, hormonal therapy can interfere with bone metabolism and induce metabolic and cardiovascular complications. Recently, new-generation hormonal therapies, such as abiraterone and enzalutamide, have been tested and approved in castration resistant prostatic cancer patients and current studies are moving forward to the earlier use of these two drugs. In this evolving scenario, the management of hormonal therapy toxicity, given the long duration of treatment and the potentially high impact of side effects on patients’ functional status and quality of life, is a critical challenge for clinicians. A correct information of patients before the initiation of treatment, together with the adoption of preventive measures, could help to ameliorate their quality of life. The aim of this review is to describe the impact on quality of life of endocrine treatment side effects and analyze possible interventions to alleviate them.

KEY WORDS: Prostatic neoplasms - MDV 3100 - Abiraterone - Quality of life